取締役及び従業員に対する譲渡制限付株式としての自己株式処分に関するお知らせ

事業報告書・株主通信 第28期 事業報告書（株主のみなさまへ）

株主総会 第28期定時株主総会 動画配信

株主総会 第28期定時株主総会終了ご通知

有価証券報告書 有価証券報告書（第28期）

ess release Correction to some of the information contained in the notice of convocation of the 28th Ordinary General Meeting of Shareholders

General meeting of shareholders Notice of Convocation of the 28th Ordinary General Meeting of Shareholders

General meeting of shareholders Materials for the 28th Ordinary General Meeting of Shareholders (Items omitted from the distributed documents)

ess release Notice Regarding the Absorption Merger of a Subsidiary of Our Consolidated Subsidiaries and Absorption Mergers Between Consolidated Subsidiaries

ess release Notice Regarding the Absorption Merger of a Subsidiary of Our Consolidated Subsidiaries and Absorption Mergers Between Consolidated Subsidiaries

ess release (Changes to Disclosure Items) Notice Regarding the Reorganization of Business Functions Following the Closure of the Kobe Research Institute

ess release Announcement Regarding Video Distribution and Publication of Materials for the FY2026 Financial Results Briefing

Earnings summary earnings summary for the fiscal year ending March 2026 [Japanese standards] (consolidated)

Materials for financial results bliefings Financial Results Presentation Materials for the Fiscal Year Ending March 2026

calendar Financial Results Briefing for the Fiscal Year Ending March 2026 - For institutional investors, analysts, and the media (held online)

Materials for financial results bliefings Video streaming of the FY2026 earnings briefing.

ess release Notice Regarding Recognition of Extraordinary Losses and Deferred Tax Assets, Differences Between Full-Year Consolidated Earnings Forecast and Actual Results, and Differences Between Individual Earnings and Previous Year's Results

ess release Notice regarding debt waiver for consolidated subsidiary

ess release Notice of US Patent Grant Regarding "Exon Humanized Mice"

ess release Notice Regarding the Closure of Transgenic Kobe Research Institute Co., Ltd. (hereinafter referred to as "Kobe Research Institute")

rmation on media publicity "Wellness Monthly Report No. 93" features an interview article with our group company, Transgenic Co., Ltd.

rmation on media publicity "Wellness Monthly Report No. 93" features an interview article with our group company, Transgenic Co., Ltd.

ess release Notice regarding change of listing market classification to the Tokyo Stock Exchange Standard Market

ess release Notice regarding approval of market classification change to the Tokyo Stock Exchange Standard Market and withdrawal of the "Plan to comply with the listing maintenance standards"

ess release Announcement of video streaming and publication of materials for the third quarter financial results briefing for the fiscal year ending March 2026

Earnings summary earnings summary for the third quarter of the fiscal year ending March 31, 2026 [Japanese GAAP] (consolidated)

Materials for financial results bliefings Third Quarter Financial Results Briefing for the Fiscal Year Ending March 2026 Video Streaming

Materials for financial results bliefings Third Quarter Financial Results Briefing for the Fiscal Year Ending March 2026

Research and development column History of Liver-Humanized Mice Episode 20, Extra Part 2

Note New Year Greetings

Note New Year Greetings

ess release Update (change) of the plan to comply with the listing maintenance standards

ess release Results of GLP Compliance Inspection at TransGenic Co., Ltd., a Subsidiary of Our Company

calendar Third Quarter Financial Results Briefing for the Fiscal Year Ending March 2026 - For institutional investors, analysts, and the media (online)

Business Report / Integrated Report 28th Interim Report

Securities report Semi-Annual Report (28th Term, 2nd Quarter)

Earnings summary earnings summary for the second quarter (interim period) of the fiscal year ending March 2026 [Japanese GAAP] (consolidated)

Materials for financial results bliefings Video streaming of the interim financial results briefing for the fiscal year ending March 2026

ess release Announcement of video streaming and publication of materials for the second quarter financial results briefing for the fiscal year ending March 2026

Materials for financial results bliefings Interim financial results briefing materials for the fiscal year ending March 2026

Materials for financial results bliefings Interim financial results briefing materials for the fiscal year ending March 2026

calendar Interim Financial Results Briefing for the Fiscal Year Ending March 2026 - For institutional investors, analysts, and the media (held online)

ess release Notice regarding business collaboration agreement between our company and its consolidated subsidiary, Transgenic Inc., and Hokkaido System Science Co., Ltd.

ess release Notice regarding business collaboration agreement between our company and its consolidated subsidiary, Transgenic Inc., and Hokkaido System Science Co., Ltd.

ess release Notice regarding the expansion of the business partnership between our company (including group companies) and A-Cell Co., Ltd. - Building a new evaluation system through collaboration between "non-clinical trials and human cell evaluation" -

ess release Notice regarding the expansion of the business partnership between our company (including group companies) and A-Cell Co., Ltd. - Building a new evaluation system through collaboration between "non-clinical trials and human cell evaluation" -

ess release Termination of telephone support for IR inquiries

ess release Patent for "Exon-humanized mice" granted in Europe

ess release Patent for "Exon-humanized mice" granted in Europe

Earnings summary earnings summary for the first quarter of the fiscal year ending March 31, 2026 [Japanese GAAP] (consolidated)

ess release Announcement of video streaming and publication of materials for the first quarter financial results briefing for the fiscal year ending March 2026

Materials for financial results bliefings First Quarter Financial Results Briefing for the Fiscal Year Ending March 2026 Video Streaming

Materials for financial results bliefings First Quarter Financial Results Briefing for the Fiscal Year Ending March 2026

General meeting of shareholders Notice of the End of the 27th Ordinary General Meeting of Shareholders

General meeting of shareholders Video streaming of the 27th Ordinary General Meeting of Shareholders continuation session

Business Report / Integrated Report 27th Business Report (To Shareholders)

ess release Notice regarding the conclusion of a joint research agreement between our consolidated subsidiary, Transgenic Inc., CLEA Japan, Inc., and the Central Institute for Experimental Animal Science (CIEA) regarding the creation of a new carcinogenicity evaluation system using rasH2 mice

ess release Notice regarding the conclusion of a joint research agreement between our consolidated subsidiary, Transgenic Inc., CLEA Japan, Inc., and the Central Institute for Experimental Animal Science (CIEA) regarding the creation of a new carcinogenicity evaluation system using rasH2 mice

ess release Notice regarding the conclusion of a joint research agreement between our consolidated subsidiary, Transgenic Inc., CLEA Japan, Inc., and the Central Institute for Experimental Animal Science (CIEA) regarding the creation of a new carcinogenicity evaluation system using rasH2 mice

ess release Notice regarding business collaboration between our company (including group companies) and A-CELL Co., Ltd. ~ Building a new functionality evaluation system through collaboration between "food clinical trials x human cell evaluation" ~

ess release Notice regarding business collaboration between our company (including group companies) and A-CELL Co., Ltd. ~ Building a new functionality evaluation system through collaboration between "food clinical trials x human cell evaluation" ~

calendar 27th Annual General Meeting of Shareholders Continuation Meeting

General meeting of shareholders 27th Annual General Meeting of Shareholders Adjournment Meeting Materials (Omissions from the documents provided)

General meeting of shareholders Notice of the continuation meeting of the 27th Ordinary General Meeting of Shareholders

ess release Patent for "Exon-humanized mouse" granted in Japan

ess release Notice regarding the date and time of the continuation meeting of the 27th Ordinary General Meeting of Shareholders

Securities report Securities Report (27th period)

General meeting of shareholders 27th Ordinary General Meeting of Shareholders Video Streaming

General meeting of shareholders Notice of the 27th Ordinary General Meeting of Shareholders

ess release Plan for compliance with the listing maintenance criteria (entering improvement period)

ess release Notice of Shareholders' Meeting

ess release (Progress of Disclosure Items) Notice Regarding Withdrawal of Application for Change of Market Classification to the Tokyo Stock Exchange Standard Market

ess release Announcement of video distribution and publication of materials for the fiscal year ending March 2025 financial results briefing

ess release Notice regarding receipt of investigation report into misconduct at our consolidated subsidiary, formulation of preventive measures against recurrence, reduction of compensation, etc.

calendar Announcement of financial results for the fiscal year ending March 2025

Earnings summary earnings summary ending March 2025 [Japanese GAAP] (consolidated)

ess release Notice regarding commencement of new service "Short-term carcinogenicity testing using rasH2 mice" at our consolidated subsidiary, Transgenic Inc.

ess release Notice regarding the disclosure of the earnings summary ending March 2025 more than 50 days after the end of the fiscal year

ess release Notice regarding Reduction of Executive Compensation

ess release Notice regarding debt waiver for consolidated subsidiary

ess release Notice regarding revision of full-year consolidated earnings forecast due to recording of extraordinary losses, etc., and difference between individual performance and previous fiscal year results

ess release Notice regarding the decision on the date for announcing financial results for the fiscal year ending March 2025

General meeting of shareholders Notice of the 27th Ordinary General Meeting of Shareholders

ess release Notice regarding the policy for holding the continuation meeting of the 27th Ordinary General Meeting of Shareholders

ess release Notice regarding postponement of the announcement of financial results for the fiscal year ending March 2025

ess release Notice regarding changes in certified public accountants, etc.

ess release Notice regarding discontinuation (termination) of countermeasures against large-scale purchases of our company shares (takeover defense measures)

calendar Announcement of financial results for the fiscal year ending March 2025

Earnings summary earnings summary for the third quarter of the fiscal year ending March 31, 2025 [Japanese GAAP] (consolidated)

Note New Year Greetings

ess release Notification regarding application for market classification change to the Tokyo Stock Exchange Standard Market

ess release Selected as an "Excellent Site" in the Growth Markets category in Nikko Investor Relations' "2024 All Listed Company Website Quality Ranking"

Business Report / Integrated Report 27th Interim Report

Securities report Semi-Annual Report (27th Term, 2nd Quarter)

ess release Announcement of video distribution and publication of materials for the second quarter financial results briefing for the fiscal year ending March 2025

Materials for financial results bliefings FY2025 Interim Financial Results Briefing Materials

Materials for financial results bliefings FY2025 Interim Financial Results Briefing Video Streaming

Note Announcement of the launch of the website of our consolidated subsidiary company, TransGenic Co., Ltd.

Note Change of company name

Note Notice of change of our site URL (domain)

Note Regarding our company's response to the electronic provision system for general meeting materials